Xcout Intel
Rezera competitors & alternatives
The 12 closest competitors and alternatives to Rezera among biotechnology companies — ranked by similarity to what Rezera actually does, not by market-cap band.
Subscribe to see Rezera’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Rezera
Rezera Inc., formerly known as NodThera, is advancing oral anti-inflammatory NLRP3 inhibitors, including the Ruvonoflast Phase 3 development program, with headquarters in Boston.
Rezera at a glance
Rezera is a biotechnology company headquartered in United States. Xcout tracks 12 named people at Rezera, including Geoff McDonough (Chief Executive Officer).
Rezera leadership
- Geoff McDonoughChief Executive Officer
- Chris GuiffreChief Financial Officer
- Jyothis GeorgeChief Medical Officer
- Nick ClarkeChief Development Officer
- Alan P. WattFounder & Chief Scientific Officer
- David HarrisonVP, Medicinal Chemistry
6 more named people on record for Rezera, with roles, board committees and tenure — see the full roster →
Top 12 Rezera competitors
Ranked by semantic similarity — how close each company is to Rezera by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Mysthera Therapeutics AG is a biotechnology company headquartered in Basel, Switzerland, focused on developing first-in-class, oral therapeutics to treat inflammation-driven and related diseases.
Biotech
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Similar biotechnology company
Bambusa Therapeutics, Inc. is a biotechnology company focused on immunology and inflammation research, maintaining operational presence both in Boston, Massachusetts and Victoria, Australia.
Similar biotechnology company
Rinascera Therapeutics, Inc. is a clinical-stage biotechnology company located in Boston, Massachusetts, dedicated to transforming the treatment of rare genetic skin diseases.
Similar biotechnology company
Apogee Therapeutics is a biotechnology company focused on the development of therapies for inflammatory and immunology diseases. The company is headquartered in Waltham, Massachusetts.
Similar biotechnology company
Akagera Medicines is a private Delaware-registered company headquartered in Boston, Massachusetts. The company develops novel and patented liposomal formulations of antibacterial drugs.
Biotech
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.
Similar biotechnology company
Resolution Therapeutics is a biotechnology research company headquartered in Edinburgh, Scotland. The company is pioneering regenerative macrophage therapies to transform outcomes for people with inflammatory and fibrotic diseases.
Biotech
Orchard Therapeutics plc is a biopharmaceutical company with operations including a U.S. headquarters located in Boston, Massachusetts.
Similar biotechnology company
ResNovas Therapeutics is a biotechnology and therapeutics company headquartered in Alameda, California, operating within the San Francisco Bay Area.
Similar biotechnology company
Avere Therapeutics is a biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing oral therapies for the treatment of IL-23-driven inflammatory diseases.
Similar biotechnology company
GlycoEra AG is a biotechnology company focused on advancing glycan-mediated therapy through game-changing protein engineering. Headquartered in Wädenswil, Switzerland, the company also maintains an office in Newton, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Rezera and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Rezeraand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →